DrugPatentWatch Database Preview
Drugs in Development Information for Bitopertin
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Bitopertin?
Bitopertin is an investigational drug.
There have been 10 clinical trials for Bitopertin.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2010.
The most common disease conditions in clinical trials are Schizophrenia, Disease, and Compulsive Personality Disorder. The leading clinical trial sponsors are Hoffmann-La Roche, Niuvanniemi Hospital, and Karolinska Institutet.
There are thirteen US patents protecting this investigational drug and one hundred and seventy-one international patents.
Summary for Bitopertin
| US Patents | 13 |
| International Patents | 171 |
| US Patent Applications | 23 |
| WIPO Patent Applications | 10 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (2010-11-01) |
| Vendors | 49 |
Recent Clinical Trials for Bitopertin
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Beta-Thalassemia | Hoffmann-La Roche | Phase 2 |
| A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers. | Hoffmann-La Roche | Phase 1 |
| Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial. | Karolinska Institutet | Phase 2 |
Clinical Trial Summary for Bitopertin
Top disease conditions for Bitopertin
Top clinical trial sponsors for Bitopertin
US Patents for Bitopertin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Bitopertin | Start Trial | 5-HT3 receptor antagonists | Takeda Pharmaceutical Company Limited (Osaka-Shi, Osaka, JP) | Start Trial |
| Bitopertin | Start Trial | Crystalline form of 1-(1-methyl-1H-pyrazol-4-yl)-N-((IR,5S,7S)-9-methyl-3-oxa-9-azabicyclo[3.- 3.1]nonan-7-yl)-1H-indole-3-carboxamide | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Bitopertin | Start Trial | 5-HT3 receptor antagonists | Takeda Pharmaceutical Company Limited (Osaka, JP) | Start Trial |
| Bitopertin | Start Trial | Benzoyl-piperazine derivatives | Hoffmann-La Roche Inc. (Nutley, NJ) | Start Trial |
| Bitopertin | Start Trial | Benzoyl-piperazine derivatives | Hoffmann-La Roche Inc. (Nutley, NJ) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Bitopertin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Bitopertin | Argentina | 091781 | 2032-07-17 | Start Trial |
| Bitopertin | Australia | 2013290375 | 2032-07-17 | Start Trial |
| Bitopertin | Brazil | 112015001028 | 2032-07-17 | Start Trial |
| Bitopertin | Canada | 2879115 | 2032-07-17 | Start Trial |
| Bitopertin | Chile | 2015000121 | 2032-07-17 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
